ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
| Brand name | XARTEMIS XR |
|---|---|
| Active ingredient | ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE |
| Strength | 325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2014 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 8658631 | May 2032 | product |
| 8741885 | May 2032 | product |
| 9468636 | May 2032 | use U-1499 |
| 9050335 | May 2032 | product |
| 8992975 | May 2032 | product |
| 8597681 | December 2030 | product |
| 8980319 | December 2030 | product |
| 8377453 | November 2029 | product |
| 8372432 | March 2029 | product |
| 8668929 | March 2029 | use U-1499 |
| 8394408 | March 2029 | product |
| 7976870 | June 2027 | use U-1498 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.